Clinical characteristics of 6 patients with WM on ibrutinib with COVID-19 infection
| Demographics . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . |
|---|---|---|---|---|---|---|
| Age, y | 65 | 61 | 72 | 67 | 71 | 58 |
| Sex | M | M | F | F | M | M |
| Time since B-cell diagnosis, mo | 39 | 54 | 95 | 202 | 52 | 107 |
| Received treatment prior to ibrutinib for WM | No | No | Yes | Yes | No | Yes |
| Time on ibrutinib, mo | 39 | 54 | 83 | 50 | 47 | 85 |
| Dose of ibrutinib, mg/d | 420 | 420 | 420 | 420 | 420 | 140-HELD-420 |
| COVID-19 symptoms | ||||||
| Time with symptoms prior to COVID-19 diagnostic testing, d | 5 | 2 | 6 | 7 | 10 | 5 |
| Time since COVID-19 diagnostic testing, d | 24 | 20 | 17 | 28 | 13 | 29 |
| Cough | Yes | Yes | Yes | Yes | Yes | Yes |
| Fever | Yes | Yes | Yes | Yes | Yes | Yes |
| Dyspnea | No | No | No | No | No | Yes |
| Sore throat | Yes | No | No | No | No | Yes |
| Taste loss | No | No | Yes | No | Yes | No |
| Smell loss | No | No | Yes | No | Yes | No |
| Hospitalization | No | No | No | No | No | Yes |
| Required ICU admission | No | No | No | No | No | Yes |
| Required supplemental O2 | No | No | No | No | No | Yes |
| Required mechanical ventilation | No | No | No | No | No | Yes |
| Other COVID-19 symptoms | No | Anorexia | Diarrhea | Headache | No | No |
| Other medication for COVID-19 | HCQ, AZ | NA | No | NA | No | HCQ, AZ, TOCI |
| Disposition | ||||||
| COVID-19 symptoms resolved | No | Yes | Yes | Yes | Yes | No |
| COVID-19 symptoms persist | Yes | No | Yes | Yes | No | Yes |
| COVID-19 symptoms improved | Yes | Yes | Yes | Yes | Yes | Yes |
| Demographics . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . |
|---|---|---|---|---|---|---|
| Age, y | 65 | 61 | 72 | 67 | 71 | 58 |
| Sex | M | M | F | F | M | M |
| Time since B-cell diagnosis, mo | 39 | 54 | 95 | 202 | 52 | 107 |
| Received treatment prior to ibrutinib for WM | No | No | Yes | Yes | No | Yes |
| Time on ibrutinib, mo | 39 | 54 | 83 | 50 | 47 | 85 |
| Dose of ibrutinib, mg/d | 420 | 420 | 420 | 420 | 420 | 140-HELD-420 |
| COVID-19 symptoms | ||||||
| Time with symptoms prior to COVID-19 diagnostic testing, d | 5 | 2 | 6 | 7 | 10 | 5 |
| Time since COVID-19 diagnostic testing, d | 24 | 20 | 17 | 28 | 13 | 29 |
| Cough | Yes | Yes | Yes | Yes | Yes | Yes |
| Fever | Yes | Yes | Yes | Yes | Yes | Yes |
| Dyspnea | No | No | No | No | No | Yes |
| Sore throat | Yes | No | No | No | No | Yes |
| Taste loss | No | No | Yes | No | Yes | No |
| Smell loss | No | No | Yes | No | Yes | No |
| Hospitalization | No | No | No | No | No | Yes |
| Required ICU admission | No | No | No | No | No | Yes |
| Required supplemental O2 | No | No | No | No | No | Yes |
| Required mechanical ventilation | No | No | No | No | No | Yes |
| Other COVID-19 symptoms | No | Anorexia | Diarrhea | Headache | No | No |
| Other medication for COVID-19 | HCQ, AZ | NA | No | NA | No | HCQ, AZ, TOCI |
| Disposition | ||||||
| COVID-19 symptoms resolved | No | Yes | Yes | Yes | Yes | No |
| COVID-19 symptoms persist | Yes | No | Yes | Yes | No | Yes |
| COVID-19 symptoms improved | Yes | Yes | Yes | Yes | Yes | Yes |
140-HELD-420 denotes that this patient was on 140 mg/d of ibrutinib prior to hospitalization that was held upon admission; he experienced worsening hypoxia after ibrutinib was held and required mechanical ventilation, following which he was restarted on 420 mg/d of ibrutinib and showed rapid improvement in oxygenation.
AZ, azithromycin; F, female; HCQ, hydroxychloroquine; ICU, Intensive Care Unit; M, male; TOCI, tocilizumab.